Current Report Filing (8-k)
May 02 2019 - 7:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
May 2, 2019
BIOSCRIP,
INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-11993
|
05-0489664
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(Employer Identification Number)
|
1600 Broadway, Suite 700, Denver, Colorado
80202
(Address of principal executive offices)
(720) 697-5200
(Registrant's telephone number, including
area code)
Not applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value per share
|
BIOS
|
Nasdaq Global Market
|
Rights to Purchase Series D Junior Participating Preferred Stock
|
Not applicable
|
Nasdaq Global Market
|
Item 2.02. Results of Operations and Financial Condition.
On May 2, 2019, BioScrip, Inc. (the “Company”)
issued a press release reporting its first quarter 2019 financial results. A copy of the press release is furnished with this Current
Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
The press release includes certain non-GAAP financial measures
as described therein. Reconciliation between any non-GAAP financial measures presented and the most directly comparable GAAP financial
measures is also provided.
Item 9.01. Financial Statements and
Exhibits
(d) Exhibits
As provided in General Instruction B.2 to Form 8-K, the information
furnished in Item 2.02 and in Exhibit 99.1 hereto, as it relates to the Company’s financial results for the quarter ended
March 31, 2019, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed
incorporated by reference into any filing of the Company with the Securities and Exchange Commission under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly provided by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOSCRIP, INC.
|
|
|
|
|
|
|
|
|
|
Date: May 2, 2019
|
By:
|
/s/ Kathryn M. Stalmack
|
|
|
|
Kathryn M. Stalmack
|
|
|
|
Senior Vice President, General Counsel and Secretary
|
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Sep 2023 to Sep 2024